Dr. Dan S. Gombos, MD

Dr. Gombos practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Gombos' NPI, 1861591554, was assigned on September 21, 2006. Dr. Gombos graduated from Stanford University School Of Medicine in 1994. Dr. Gombos holds Texas license L3662.

Dr. Gombos' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Gombos' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Texas Children's Hospital. Dmand AI also links Dr. Gombos to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gombos practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Gombos' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Gombos is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Gombos' licenses on file in 4 states: Texas, California, Oklahoma and Pennsylvania.

Dmand AI lists dry eye, eyelid inflammation, glaucoma, laser destruction of retinal or choroid lesions, vision problems and vitreous eye degeneration among the conditions Dr. Gombos treats.

CMS data shows 1,418 Medicare services from Dr. Gombos across 13 procedure codes in 2024, for 286 Medicare patients. Medicare paid $34,731 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 286 Medicare patients who saw Dr. Gombos in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gombos' median patient age at 71, with 53% women.

In 2024, Dr. Gombos wrote 20 Medicare Part D claims for 11 patients. 65% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Gombos for performance year 2024, reported as part of a group. Dr. Gombos accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 89 papers to Dr. Gombos, published from 2006 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Retinoblastoma, Retinal Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Gombos has published most often in Ophthalmology. Dr. Gombos' most frequent co-authors are Murali Chintagumpala, MD, Nagham Al-Zubidi, MD and Patricia Chevez-Barrios, MD.

Dmand AI links Dr. Gombos to 1 clinical trial. Conditions studied include Retinal Neoplasms and Retinoblastoma.

CMS Open Payments shows 16 general payments to Dr. Gombos from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Abbvie Inc. paid the most, $3,052.

Dmand AI lists 2 awards for Dr. Gombos.

Dr. Gombos graduated from Stanford University School Of Medicine in 1994. Dr. Gombos is a member of AAO and ACS.

Dr. Gombos is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.